Author Correction: Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial. - Usmani SZ; Facon T; Hungria V; Bahlis NJ; Venner CP; Braunstein M; Pour L; Martí JM; Basu S; Cohen YC; Matsumoto M; Suzuki K; et al. (Nature medicine, 2025)